Vioxx (rofecoxib) - May 6, 2002
May 6, 2002
Audience: Healthcare professionals treating patients with osteoarthritis, rheumatoid arthritis, acute pain, and primary dysmenorrhea
FDA and Merck strengthened the WARNINGS, PRECAUTIONS, and CLINICAL STUDIES sections of Vioxx labeling to describe new cardiovascular and gastroenterological safety information. This information reflected the results of a prospective, active control study of Vioxx 50 mg daily versus naproxen 500 mg twice daily and from a placebo-controlled trials database. This information should be taken into consideration and caution should be exercised when Vioxx is used in patients with a medical history of ischemic heart disease.[April 11, 2002 Talk Paper - FDA]
[April, 2002 Letter - Merck] 48 KB PDF file
[April, 2002 Full, revised, highlighted label - Merck] 2.4 MB PDF file
[April, 2002 Patient Package Insert, highlighted - Merck] 31 KB PDF file
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.